证券代码：300199 证券简称：翰宇药业 公告编号：2025-058 深圳翰宇药业股份有限公司 2025年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生。 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 1、2025年10月21日，深圳翰宇药业股份有限公司（以下简称"公司"或"翰 宇药业"）第六届董事会第八次会议审议通过《关于提请召开2025年第三次临 时股东大会的议案》，详见公司2025年10月22日在中国证监会指定信息披露 网站（http://www.cninfo.com.cn）披露的相关公告。 2025年第三次临时股东大会召开的基本情况如下： 会议召集人：公司董事会 会议方式：本次会议采取现场投票和网络投票相结合的方式 2、通过现场和网络投票的股东1,012人，代表股份206,360,091股，占公 司有表决权股份总数的23.3640％。 其中：通过现场投票的股东7人，代表股份183,963,022股，占公司有表决 权股份总数的20.8282％。 ...

Core Viewpoint - The A-share market shows a collective increase in major indices, with notable performance in the ChiNext Growth ETF, indicating positive investor sentiment and capital inflow into growth sectors [1]. Market Performance - As of November 6, 2025, the Shanghai Composite Index rose by 0.89%, the Shenzhen Component Index increased by 1.65%, and the ChiNext Index gained 1.81% [1]. - The ChiNext Growth ETF (159967) saw a rise of 2.69%, with a latest price of 0.61 yuan and a trading volume of 2.23 billion yuan, reflecting a turnover rate of 6.99% [1]. Stock Performance - Among the constituent stocks, notable gainers included: - Xiechuang Data up by 9.65% - Oulutong up by 9.16% - Feiliwa up by 7.37% - Shenghong Technology up by 5.87% - Guangku Technology up by 5.72% - Conversely, losers included: - Lepu Medical down by 3.69% - Hanyu Pharmaceutical down by 2.25% - Shunwang Technology down by 1.63% - Light Media down by 0.87% - Runhe Software down by 0.84% [1]. Capital Inflow - The ChiNext Growth ETF has experienced net capital inflow for seven consecutive trading days, with a peak single-day inflow of 0.87 billion yuan, totaling 2.14 billion yuan [1]. Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the ChiNext Growth ETF is 39.04 times, which is below the 40.11% percentile of the past ten years, indicating that the valuation is lower than 59.89% of the time over the last decade [1]. Sector Weighting - The index tracked by the ChiNext Growth ETF is heavily weighted in the following sectors: - Communication: 36.69% - Power Equipment: 20.11% - Electronics: 12.66% - Non-bank Financials: 10.96% - Computers: 9.05% [1].

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology sector, with a focus on the continued investment in domestic innovative drugs by multinational corporations (MNCs) [2]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.31%, outperforming the Wind All A index (0.41%) and the CSI 300 index (-0.43%). Key sub-sectors leading the gains included vaccines (3.38%), other biological products (3.33%), and chemical preparations (3.31%). Conversely, medical consumables (-1.98%), offline pharmacies (-1.84%), and medical devices (-1.45%) experienced declines [2][7]. - MNCs are increasingly investing in domestic innovative drugs, with significant collaborations and licensing agreements being established. Notable deals include the licensing of MWN105 by Lepu Medical to Sidera Bio, and Pfizer's registration of two global Phase III clinical studies for a dual antibody from 3SBio [2][12][13]. - Flu activity is on the rise, particularly in southern provinces, with reported ILI percentages indicating an increase compared to previous weeks and years [2][12]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector rose by 1.31%, outperforming the Wind All A index and the CSI 300 index. The leading sub-sectors were vaccines, other biological products, and chemical preparations, while medical consumables, offline pharmacies, and medical devices lagged [7][8][9]. Industry News and Key Company Announcements - Significant events include the initiation of the 2025 National Medical Insurance Directory negotiations, which will include a new category for innovative drugs under commercial health insurance [12]. - Lepu Medical's subsidiary licensed its innovative weight-loss drug MWN105 to Sidera Bio, with potential milestone payments reaching up to $1.01 billion [12][13]. - Pfizer registered two Phase III clinical studies for a dual antibody targeting advanced lung cancer and colorectal cancer [12][13]. - Roche entered a global exclusive collaboration with QX031N, a dual antibody developed by Qianxin Bio, with potential milestone payments of up to $995 million [12][13].

Core Insights - The report highlights the potential for collaboration between China and the United States to address significant global issues, emphasizing the importance of joint efforts in various sectors [4] - The revenue of large-scale cultural enterprises in China increased by 7.9% year-on-year in the first three quarters [4] - The establishment of a special fund for strategic emerging industries by state-owned enterprises is expected to support the aerospace industry, with specific stocks identified as potential beneficiaries [5] Industry Updates - The "robotics + AI + low-altitude" integration is expected to open new market opportunities, with solid-state battery industrialization anticipated to accelerate, highlighting related stocks [5] - The storage sector in the U.S. continues to perform well, with institutions predicting a significant improvement in the performance of storage-related stocks [5] Company Focus - Tianyu Co., Ltd. reported a net profit of 71.42 million yuan for the third quarter, representing a year-on-year increase of 123.9% [6] - Mingyang Circuit achieved a net profit of 32.98 million yuan in the third quarter, marking a year-on-year growth of 1121.3% [6] - Tianqi Lithium Industries recorded a net profit of 180 million yuan in the first three quarters, supported by forward-looking strategic planning [6] - Hanyu Pharmaceutical reported an operating income of 683 million yuan in the first three quarters of 2025, with operating cash flow reaching a historical high for the same period [6] Market Review and Outlook - On October 30, the market experienced fluctuations, with major indices showing declines, particularly the ChiNext Index which fell nearly 2% [7] - The total trading volume in the Shanghai and Shenzhen markets reached 2.42 trillion yuan, an increase of 165.6 billion yuan compared to the previous trading day [7] - The report notes a mixed performance across sectors, with lithium mining stocks gaining strength while computing hardware stocks faced declines [7] - The overall market sentiment remains cautious, with a focus on performance growth and cyclical stock styles attracting more capital [7]

Market Overview - A-shares experienced a decline on October 30, with the Shanghai Composite Index falling below the 4000-point mark, closing down 0.73% at 3986.9 points, and the Shenzhen Component Index down 1.16% at 13532.13 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 24.646 billion yuan, an increase of 1.737 billion yuan compared to the previous day [1] Sector Performance - The coal sector saw significant declines, with companies like Kailuan Energy and Antai Group hitting the daily limit down [1] - The brokerage sector weakened, with firms such as China International Capital Corporation and East Money falling over 3% [1] - The AI industry chain stocks plummeted, with companies like Tengjing Technology and Tianfu Communication dropping over 10% [1] - Conversely, the steel and non-ferrous metal sectors experienced gains, with companies like Chang Aluminum and Dazhong Mining hitting the daily limit up [1] Lithium Battery Sector - The lithium battery industry chain stocks surged, with Penghui Energy hitting the daily limit up at 20%, and Tianhua New Energy rising nearly 15% [3][4] - The overall performance of lithium battery stocks indicates a strong market demand, driven by seasonal increases in household energy storage battery needs and the growth of AI computing centers [3][5] Quantum Technology Sector - Quantum technology stocks became active again, with Fujida rising nearly 20% and Guodun Quantum surpassing 600 yuan, setting a new historical high [6][7] - The recent government proposals emphasize the importance of quantum technology as a future industry, suggesting potential for further policy support and investment opportunities [8] Innovative Drug Sector - The innovative drug sector faced a downturn, with Hanyu Pharmaceutical dropping over 10% and WuXi AppTec falling over 8% [9] - Hanyu Pharmaceutical reported a revenue of 683 million yuan for the first three quarters, a year-on-year increase of 82.06%, but reported a net loss in the third quarter [9]

Market Overview - A-shares experienced a decline on October 30, with the Shanghai Composite Index falling below the 4000-point mark, and the ChiNext and STAR Market indices dropping nearly 2% [1][2] - The Shanghai Composite Index closed down 0.73% at 3986.9 points, while the Shenzhen Component Index fell 1.16% to 13532.13 points [2] Sector Performance - The coal sector saw significant declines, with companies like Kailuan Energy and Antai Group hitting the daily limit down [2] - The brokerage sector weakened, with firms such as China International Capital Corporation and Oriental Fortune dropping over 3% [2] - The AI industry chain stocks plummeted, with companies like Tengjing Technology and Tianfu Communication falling over 10% [2] - The innovative drug concept also faced downturns, with Hanyu Pharmaceutical dropping over 10% and WuXi AppTec falling over 8% [2][13] Lithium Battery Sector - The lithium battery industry chain stocks surged, with Penghui Energy hitting the daily limit up with a 20% increase, and Tianhua New Energy rising nearly 15% [5][6] - Other notable performers included Wanrun New Energy and Xinwangda, both rising over 10% [5] - The overall market for lithium battery stocks is bolstered by increasing demand for household energy storage batteries and the growth of AI computing centers [7] Quantum Technology Sector - The quantum technology sector saw renewed activity, with Fujida rising nearly 20% and Guodun Quantum exceeding a 17% increase, reaching a price above 600 yuan [9][10] - The government has emphasized the importance of quantum technology in future economic growth, with expected policy support [11] Innovative Drug Sector - The innovative drug sector showed weakness, with Hanyu Pharmaceutical reporting a significant drop in stock price despite a strong revenue growth of 82.06% year-on-year [13] - WuXi AppTec announced plans for a share reduction by its controlling shareholder, which may have contributed to its stock price decline [13]

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.28% on October 30, with Hanyu Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Stock Performance - Notable gainers included: - C Bietete (688759) with a closing price of 34.82, up 9.29% and a trading volume of 219,800 shares, totaling 732 million yuan [1] - Changshan Pharmaceutical (300255) closed at 63.50, up 8.51% with a trading volume of 493,200 shares, totaling 3.073 billion yuan [1] - Significant losers included: - Hanyu Pharmaceutical (300199) closed at 20.01, down 10.23% with a trading volume of 1,135,400 shares, totaling 232.7 million yuan [2] - Kangyi Pharmaceutical (300086) closed at 7.44, down 7.81% with a trading volume of 947,500 shares, totaling 713 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.268 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.508 billion yuan [2] - The capital flow for specific stocks showed: - Changshan Pharmaceutical had a net inflow of 74.5152 million yuan from institutional investors [3] - Hanyu Pharmaceutical experienced a net outflow of 60.3884 million yuan from retail investors [3]

Core Insights - The company reported significant growth in its financial performance for the first three quarters of 2025, with revenue reaching 683 million yuan, a year-on-year increase of 82.06%, and a net profit of 71.35 million yuan, marking a turnaround from losses [1] - The operational cash flow reached a historical high of 271 million yuan, reflecting a year-on-year growth of 207.37%, driven by the successful market penetration of its core product, liraglutide injection [1] Financial Performance - Revenue for the first three quarters was 683 million yuan, up 82.06% year-on-year [1] - Net profit attributable to shareholders was 71.35 million yuan, indicating a return to profitability [1] - Operating cash flow was 271 million yuan, representing a 207.37% increase year-on-year, the highest in the same period historically [1] Technological Innovation - The company launched a "Peptide AI Process Optimization Assistant" in collaboration with Huawei Cloud, utilizing over 100,000 historical process data points and global chemical databases to enhance drug development efficiency [2] - The AI assistant has reportedly reduced research and development cycles by 45% and lowered trial and error costs by over 20% [2] - The company is also advancing in new peptide sustained-release technologies, improving drug delivery convenience and optimizing drug action duration [2] CRDMO Business Expansion - The company has been active in the CRDMO (Contract Research, Development, and Manufacturing Organization) sector, forming strategic partnerships to enhance its business ecosystem [3] - Collaborations with Carbon Cloud Peptide focus on innovative peptide drug development, covering the entire process from preclinical research to commercialization [3] - The partnership with Borui Pharmaceutical aims to provide international standard raw material supply for oral peptide products, supporting global industrialization of innovative drugs [3] Capital Increase and Capacity Expansion - The company announced a plan to raise up to 968 million yuan through a private placement to enhance its core peptide drug business [4] - Of the raised funds, 495 million yuan will be allocated to expanding peptide drug production lines and green intelligent upgrades to ensure continuous supply of raw materials [4] - The plan also includes investing 40 million yuan in expanding peptide fragment production, aiming for vertical integration in the pharmaceutical supply chain [4]

Market Overview - A-shares showed mixed performance on October 30, with the Shanghai Composite Index rising by 0.06% and the Shenzhen Component Index and ChiNext Index declining by 0.02% and 0.23% respectively. The half-day trading volume reached 1.53 trillion yuan, an increase of 107.8 billion yuan compared to the previous trading day [1] Investment Focus - Current investment focus includes three main directions: technology growth as a core area, high-dividend defensive sectors, and cyclical sectors such as non-ferrous metals, chemicals, and steel as elastic supplements [1] Sector Performance - Quantum technology concept stocks surged, with Shenzhou Information achieving a six-day three-limit rise. Other stocks like Weide Information and Guodun Quantum also saw gains. This surge is attributed to NVIDIA's launch of NVQLink, which connects quantum computing with GPU computing [2] - The innovative drug and CRO sectors experienced declines, with WuXi AppTec dropping nearly 9%. This decline follows an announcement regarding a planned share reduction by major shareholders [3] Institutional Insights - Huatai Securities suggests a high probability of the index continuing to break upwards, driven by structural bull market characteristics and potential easing of negative market factors following US-China negotiations [4] - Huajin Securities maintains that a slow bull market and technology as the main line remain unchanged, recommending low-cost allocations in technology growth and certain cyclical sectors [5] - Everbright Securities anticipates continued upward movement in the market, with the Shanghai Composite Index surpassing 4000 points, potentially attracting more external funds [6]

Company Performance - Zhendemedical's stock price reached a historical high, increasing by 3.02% to 88.99 yuan, with a trading volume of 4.2343 million shares and a transaction value of 374 million yuan, resulting in a turnover rate of 1.59% [2] - The latest total market capitalization of Zhendemedical in A-shares is 23.711 billion yuan, with the circulating market capitalization also at 23.711 billion yuan [2] - The company's Q3 report indicates a total operating revenue of 3.184 billion yuan for the first three quarters, representing a year-on-year growth of 1.88%, while net profit decreased by 33.91% to 203 million yuan, with basic earnings per share at 0.7600 yuan and a weighted average return on equity of 3.57% [2] Industry Overview - The pharmaceutical and biotechnology industry, to which Zhendemedical belongs, experienced an overall decline of 0.86%, with 135 stocks rising and 3 stocks hitting the daily limit, including HeFu China and Aomei Medical [2] - Conversely, 345 stocks in the industry saw declines, with the largest drops recorded by Hanyu Pharmaceutical, WuXi AppTec, and Kangzhi Pharmaceutical, with declines of 8.97%, 7.71%, and 6.94% respectively [2] Margin Trading Data - As of October 29, the latest margin trading balance for Zhendemedical is 1.089 billion yuan, with a financing balance of 1.088 billion yuan, reflecting an increase of 216 million yuan over the past 10 days, which is a 24.71% increase [2]